Literature DB >> 35031966

MiR-590 suppresses the progression of non-small cell lung cancer by regulating YAP1 and Wnt/β-catenin signaling.

X Hao1, A Su2.   

Abstract

OBJECTIVE: Accumulating evidence has been revealed that miR-590 is involved in the progression and carcinogenesis of various cancers. However, the molecular mechanism of miR-590 in non-small-cell lung cancer (NSCLC) remains unclear.
METHODS: Quantitative reverse transcription-PCR (qRT-PCR), western blot, MTT, and transwell assay were applied to investigate the functional role of miR-590 in this study. Dual luciferase reporter assay was utilized to investigate the interaction between YAP1 and miR-590 expression. Cells transfected with miR-590 mimic or inhibitor were subjected to western blot to investigate the role of Wnt/β-catenin signaling in NSCLC modulated by miR-590.
RESULTS: MiR-590 was down-regulated in NSCLC tissues and cells. Kaplan-Meier analysis found that the higher expression of miR-590 in NSCLC patients, the more improved survival rate of NSCLC patients. Over-expression of miR-590 inhibited NSCLC cell proliferation, migration, and invasion. Moreover, increasing miR-590 suppressed Yes-associated protein 1 (YAP1) expression and inhibited the Wnt/β-catenin pathway in NSCLC cells. Furthermore, miR-590 was negatively correlated with YAP1 expression.
CONCLUSION: These findings demonstrated that the miR-590/YAP1 axis exerted an important role in the progression of NSCLC, suggesting that miR-590 might be the appealing prognostic marker for NSCLC treatment.
© 2021. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).

Entities:  

Keywords:  NSCLC; Progression; Wnt/β-catenin; YAP1; miR-590

Mesh:

Substances:

Year:  2022        PMID: 35031966     DOI: 10.1007/s12094-021-02713-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  31 in total

Review 1.  Cancer metastasis: building a framework.

Authors:  Gaorav P Gupta; Joan Massagué
Journal:  Cell       Date:  2006-11-17       Impact factor: 41.582

Review 2.  Epithelial-mesenchymal transition in cancer development and its clinical significance.

Authors:  Masaaki Iwatsuki; Koshi Mimori; Takehiko Yokobori; Hideshi Ishi; Toru Beppu; Shoji Nakamori; Hideo Baba; Masaki Mori
Journal:  Cancer Sci       Date:  2009-10-28       Impact factor: 6.716

Review 3.  Lung cancer in 2014: optimizing lung cancer treatment approaches.

Authors:  Rafael Rosell; Niki Karachaliou
Journal:  Nat Rev Clin Oncol       Date:  2014-12-23       Impact factor: 66.675

Review 4.  Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges.

Authors:  Marshall L Spiegel; Jonathan W Goldman; Brian R Wolf; Danielle J Nameth; Tristan R Grogan; Aaron E Lisberg; Deborah J L Wong; Blanca A Ledezma; Melody A Mendenhall; Scott J Genshaft; Antonio J Gutierrez; Fereidoun Abtin; W Dean Wallace; Carlos R Adame; Jordan R McKenzie; Phillip A Abarca; Alice J Li; Jennifer L Strunck; Sina Famenini; James M Carroll; D Andrew Tucker; Lauren M Sauer; Nima M Moghadam; David A Elashoff; Christina D Abaya; Meghan B Brennan; Edward B Garon
Journal:  Cancer       Date:  2017-11-10       Impact factor: 6.860

Review 5.  Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.

Authors:  Misako Nagasaka; Shirish M Gadgeel
Journal:  Expert Rev Anticancer Ther       Date:  2017-11-26       Impact factor: 4.512

6.  Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer.

Authors:  Da Yang; Yan Sun; Limei Hu; Hong Zheng; Ping Ji; Chad V Pecot; Yanrui Zhao; Sheila Reynolds; Hanyin Cheng; Rajesha Rupaimoole; David Cogdell; Matti Nykter; Russell Broaddus; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Jinsong Liu; Ilya Shmulevich; Anil K Sood; Kexin Chen; Wei Zhang
Journal:  Cancer Cell       Date:  2013-02-11       Impact factor: 31.743

Review 7.  Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.

Authors:  Stephanie Y Brule; Khalid Al-Baimani; Hannah Jonker; Tinghua Zhang; Garth Nicholas; Glenwood Goss; Scott A Laurie; Paul Wheatley-Price
Journal:  Lung Cancer       Date:  2016-04-14       Impact factor: 5.705

Review 8.  Lung cancer: current therapies and new targeted treatments.

Authors:  Fred R Hirsch; Giorgio V Scagliotti; James L Mulshine; Regina Kwon; Walter J Curran; Yi-Long Wu; Luis Paz-Ares
Journal:  Lancet       Date:  2016-08-27       Impact factor: 79.321

Review 9.  Epithelial-mesenchymal transition and its implications for fibrosis.

Authors:  Raghu Kalluri; Eric G Neilson
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

Review 10.  The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer.

Authors:  Vinicius Ernani; Conor E Steuer; Mohammad Jahanzeb
Journal:  Annu Rev Med       Date:  2016-09-07       Impact factor: 13.739

View more
  1 in total

1.  miR-29a-3p inhibits the malignant characteristics of non-small cell lung cancer cells by reducing the activity of the Wnt/β-catenin signaling pathway.

Authors:  Kang Zhang; Xiaoliang Han; Wenbin Hu; Chao Su; Binjun He
Journal:  Oncol Lett       Date:  2022-09-12       Impact factor: 3.111

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.